FDA’s Strategic Retreat In Off-Label Case: Concedes Broader Use of Exparel, Gets Firm To File sNDA
This article was originally published in RPM Report
Executive Summary
FDA’s settlement of the latest off-label suit filed by Pacira is being read as the latest victory by First Amendment advocates in industry. But it is more of a strategic retreat than an outright defeat for FDA.